The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 12, 2026
Snapshot (as of Oct 12, 2026): Takeda Pharmaceutical Company Limited (TKPHF) pays a $200.00 annual dividend, yielding 3.81% at $33.85/share. Next ex-dividend date 2027-03-31. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 3.81%
Annual Dividend: $200.00 per share
Payout Ratio: 280.2% (based on depressed trailing earnings — see safety analysis below)
Ex-Dividend Date: 2027-03-31
Dividend Frequency: semi-annually
Sector: Healthcare
Years of Dividend History: 41
Takeda Pharmaceutical Company Limited dividend has been a feature of one of Japan's oldest pharmaceutical companies, founded in 1781 and now operating across gastroenterology, rare diseases, oncology, and neuroscience with brands like Entyvio, Vyvanse, and Takhzyro. The current yield sits at 3.81%, placing TKPHF in moderate-yield territory for income investors. Payments arrive semi-annually, with the last dividend of $0.6480 per share and the next ex-dividend date set for March 31, 2027. A beta of 0.1 means the stock moves very little with the broader market, which appeals to investors who prioritize low volatility over high growth.
Takeda Pharmaceutical Company Limited pays out 280.2% of earnings as dividends, a payout ratio classified as high (above 75%). That figure is well above 100%, meaning current earnings alone do not cover the dividend. Takeda Pharmaceutical Company Limited dividend safety is a legitimate concern here, as the company operates across capital-intensive areas including plasma-derived therapies, rare disease treatments, and vaccine development, none of which guarantee near-term earnings recovery. The most significant data-supported pressure is the payout ratio itself: at 280.2%, any further earnings compression leaves little room before the dividend faces structural stress.
Takeda Pharmaceutical Company Limited dividend history shows a CAGR of 2.7% per year from 2008 to 2025. Per-share payments moved from $1.6763 to $2.6428 over that period (with 2026 a partial year and not included in the CAGR calculation). The history table also contains at least one year-over-year decline exceeding 5%, confirming this is not an unbroken growth record. Growth is slow, and the absence of consecutive annual increases means TKPHF does not qualify as a Dividend Aristocrat.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +24.9% | $1.36 (2022) | $2.64 (2025) |
| 5-Year | +9.4% | $1.69 (2020) | $2.64 (2025) |
| 10-Year | +5.8% | $1.50 (2015) | $2.64 (2025) |
TKPHF fits income-focused investors who want pharmaceutical sector exposure with low market sensitivity, not those chasing dividend growth. The yield of 3.81% is moderate (2-4%), and it currently sits below the 5-year average of 4.47%, which means buyers today are accepting a lower starting yield than the stock has historically offered. The payout ratio of 280.2% is the defining trade-off: income arrives semi-annually from a company with a broad global product portfolio, but the earnings coverage is thin. An investor gains a low-beta income stream tied to a diversified pharmaceutical business; they accept meaningful payout sustainability risk in exchange.
| Payment Date | Amount per Share |
|---|---|
| 2027-03-30 | $0.6421 |
| 2026-09-29 | $0.6480 |
| 2026-03-31 | $0.6286 |
| 2025-09-30 | $0.6758 |
| 2025-09-29 | $0.6690 |
| 2025-03-31 | $0.6490 |
| 2025-03-28 | $0.6490 |
| 2024-09-30 | $0.6770 |
| 2024-09-27 | $0.6770 |
| 2024-03-28 | $0.6220 |
| Year | Total Dividends |
|---|---|
| 2027 | $0.6421 |
| 2026 | $1.2766 |
| 2025 | $2.6428 |
| 2024 | $1.9760 |
| 2023 | $1.3076 |
Project income from TKPHF with the TKPHF dividend calculator or track your full portfolio with the dividend tracker.